市場調査レポート
商品コード
1352713

セリアック病治療薬の世界市場 2023-2027

Global Celiac Diseases Drugs Market 2023-2027

出版日: | 発行: TechNavio | ページ情報: 英文 155 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
セリアック病治療薬の世界市場 2023-2027
出版日: 2023年09月21日
発行: TechNavio
ページ情報: 英文 155 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

セリアック病治療薬市場は2022-2027年に7億159万米ドル、予測期間中のCAGRは17.01%で成長すると予測されます。

この調査レポートは、セリアック病治療薬市場の全体分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、グルテンを含む食品の消費量の増加、セリアック病の有病率の増加、政府の取り組みによって牽引されています。

市場範囲
基準年 2022
終了年 2027
予測期間 2023-2027
成長モメンタム 加速
前年比 15.85%
CAGR 17.01%
増分額 7億159万米ドル

本調査では、今後数年間のセリアック病治療薬市場成長を牽引する主要因の一つとして、無機的成長戦略を挙げています。また、セリアック治療における有望な開発、有病率の上昇、診断の増加は、市場の大きな需要につながります。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2022
  • 市場の見通し 2022-2027

第4章 市場規模実績

  • セリアック病治療薬の世界市場 2017-2021
  • 療法セグメント分析 2017-2021
  • 投与経路セグメント分析 2017-2021
  • 地域別セグメント分析 2017-2021
  • 国別セグメント分析 2017-2021

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 市場セグメンテーション:療法別

  • 市場セグメント
  • 比較:療法別
  • 第1選択治療:市場規模と予測 2022-2027
  • 第2選択治療:市場規模と予測 2022-2027
  • 市場機会:療法別

第7章 市場セグメンテーション:投与経路別

  • 市場セグメント
  • 比較:投与経路別
  • 経口:市場規模と予測 2022-2027
  • 非経口:市場規模と予測 2022-2027
  • 市場機会:投与経路別

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米:市場規模と予測 2022-2027
  • 欧州:市場規模と予測 2022-2027
  • アジア:市場規模と予測 2022-2027
  • 世界のその他の地域:市場規模と予測 2022-2027
  • 米国:市場規模と予測 2022-2027
  • カナダ:市場規模と予測 2022-2027
  • ドイツ:市場規模と予測 2022-2027
  • 英国:市場規模と予測 2022-2027
  • 中国:市場規模と予測 2022-2027
  • 市場機会:地域情勢別

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Adaptive Biotechnologies Corp.
  • Almirall SA
  • Amgen Inc.
  • AMYRA Biotech AG
  • BioLineRx Ltd.
  • Bristol Myers Squibb Co.
  • Calypso Biotech BV
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • ImmunogenX Inc.
  • Johnson and Johnson
  • Precigen Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Therapy
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Route of Administration
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits18: Historic Market Size - Data Table on global celiac diseases drugs market 2017 - 2021 ($ million)
  • Exhibits19: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
  • Exhibits20: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
  • Exhibits23: Five forces analysis - Comparison between 2022 and 2027
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • Exhibits29: Chart on Market condition - Five forces 2022 and 2027
  • Exhibits30: Chart on Therapy - Market share 2022-2027 (%)
  • Exhibits31: Data Table on Therapy - Market share 2022-2027 (%)
  • Exhibits32: Chart on Comparison by Therapy
  • Exhibits33: Data Table on Comparison by Therapy
  • Exhibits34: Chart on First line treatment - Market size and forecast 2022-2027 ($ million)
  • Exhibits35: Data Table on First line treatment - Market size and forecast 2022-2027 ($ million)
  • Exhibits36: Chart on First line treatment - Year-over-year growth 2022-2027 (%)
  • Exhibits37: Data Table on First line treatment - Year-over-year growth 2022-2027 (%)
  • Exhibits38: Chart on Second-line treatment - Market size and forecast 2022-2027 ($ million)
  • Exhibits39: Data Table on Second-line treatment - Market size and forecast 2022-2027 ($ million)
  • Exhibits40: Chart on Second-line treatment - Year-over-year growth 2022-2027 (%)
  • Exhibits41: Data Table on Second-line treatment - Year-over-year growth 2022-2027 (%)
  • Exhibits42: Market opportunity by Therapy ($ million)
  • Exhibits43: Data Table on Market opportunity by Therapy ($ million)
  • Exhibits44: Chart on Route of Administration - Market share 2022-2027 (%)
  • Exhibits45: Data Table on Route of Administration - Market share 2022-2027 (%)
  • Exhibits46: Chart on Comparison by Route of Administration
  • Exhibits47: Data Table on Comparison by Route of Administration
  • Exhibits48: Chart on Oral - Market size and forecast 2022-2027 ($ million)
  • Exhibits49: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
  • Exhibits50: Chart on Oral - Year-over-year growth 2022-2027 (%)
  • Exhibits51: Data Table on Oral - Year-over-year growth 2022-2027 (%)
  • Exhibits52: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
  • Exhibits53: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
  • Exhibits54: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
  • Exhibits55: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)
  • Exhibits56: Market opportunity by Route of Administration ($ million)
  • Exhibits57: Data Table on Market opportunity by Route of Administration ($ million)
  • Exhibits58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits59: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibits60: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibits61: Chart on Geographic comparison
  • Exhibits62: Data Table on Geographic comparison
  • Exhibits63: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits65: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits66: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits67: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits68: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits69: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits70: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits73: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits74: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits79: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits80: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits81: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibits82: Data Table on US - Year-over-year growth 2022-2027 (%)
  • Exhibits83: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits84: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits85: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits86: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits87: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits88: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits89: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits90: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits91: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits92: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits93: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits94: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits95: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits96: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits97: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibits98: Data Table on China - Year-over-year growth 2022-2027 (%)
  • Exhibits99: Market opportunity By Geographical Landscape ($ million)
  • Exhibits100: Data Tables on Market opportunity By Geographical Landscape ($ million)
  • Exhibits101: Impact of drivers and challenges in 2022 and 2027
  • Exhibits102: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits103: Overview on factors of disruption
  • Exhibits104: Impact of key risks on business
  • Exhibits105: Vendors covered
  • Exhibits106: Matrix on vendor position and classification
  • Exhibits107: Adaptive Biotechnologies Corp. - Overview
  • Exhibits108: Adaptive Biotechnologies Corp. - Product / Service
  • Exhibits109: Adaptive Biotechnologies Corp. - Key offerings
  • Exhibits110: Almirall SA - Overview
  • Exhibits111: Almirall SA - Product / Service
  • Exhibits112: Almirall SA - Key news
  • Exhibits113: Almirall SA - Key offerings
  • Exhibits114: Amgen Inc. - Overview
  • Exhibits115: Amgen Inc. - Product / Service
  • Exhibits116: Amgen Inc. - Key offerings
  • Exhibits117: AMYRA Biotech AG - Overview
  • Exhibits118: AMYRA Biotech AG - Product / Service
  • Exhibits119: AMYRA Biotech AG - Key offerings
  • Exhibits120: BioLineRx Ltd. - Overview
  • Exhibits121: BioLineRx Ltd. - Product / Service
  • Exhibits122: BioLineRx Ltd. - Key offerings
  • Exhibits123: Bristol Myers Squibb Co. - Overview
  • Exhibits124: Bristol Myers Squibb Co. - Product / Service
  • Exhibits125: Bristol Myers Squibb Co. - Key news
  • Exhibits126: Bristol Myers Squibb Co. - Key offerings
  • Exhibits127: Calypso Biotech BV - Overview
  • Exhibits128: Calypso Biotech BV - Product / Service
  • Exhibits129: Calypso Biotech BV - Key offerings
  • Exhibits130: GlaxoSmithKline Plc - Overview
  • Exhibits131: GlaxoSmithKline Plc - Business segments
  • Exhibits132: GlaxoSmithKline Plc - Key news
  • Exhibits133: GlaxoSmithKline Plc - Key offerings
  • Exhibits134: GlaxoSmithKline Plc - Segment focus
  • Exhibits135: Glenmark Pharmaceuticals Ltd. - Overview
  • Exhibits136: Glenmark Pharmaceuticals Ltd. - Product / Service
  • Exhibits137: Glenmark Pharmaceuticals Ltd. - Key offerings
  • Exhibits138: ImmunogenX Inc. - Overview
  • Exhibits139: ImmunogenX Inc. - Product / Service
  • Exhibits140: ImmunogenX Inc. - Key offerings
  • Exhibits141: Johnson and Johnson - Overview
  • Exhibits142: Johnson and Johnson - Business segments
  • Exhibits143: Johnson and Johnson - Key news
  • Exhibits144: Johnson and Johnson - Key offerings
  • Exhibits145: Johnson and Johnson - Segment focus
  • Exhibits146: Precigen Inc. - Overview
  • Exhibits147: Precigen Inc. - Business segments
  • Exhibits148: Precigen Inc. - Key offerings
  • Exhibits149: Precigen Inc. - Segment focus
  • Exhibits150: Sanofi - Overview
  • Exhibits151: Sanofi - Business segments
  • Exhibits152: Sanofi - Key news
  • Exhibits153: Sanofi - Key offerings
  • Exhibits154: Sanofi - Segment focus
  • Exhibits155: Takeda Pharmaceutical Co. Ltd. - Overview
  • Exhibits156: Takeda Pharmaceutical Co. Ltd. - Product / Service
  • Exhibits157: Takeda Pharmaceutical Co. Ltd. - Key news
  • Exhibits158: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibits159: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibits160: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibits161: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibits162: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits163: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibits164: Inclusions checklist
  • Exhibits165: Exclusions checklist
  • Exhibits166: Currency conversion rates for US$
  • Exhibits167: Research methodology
  • Exhibits168: Validation techniques employed for market sizing
  • Exhibits169: Information sources
  • Exhibits170: List of abbreviations
目次
Product Code: IRTNTR45214

The celiac diseases drugs market is forecasted to grow by USD 701.59 mn during 2022-2027, accelerating at a CAGR of 17.01% during the forecast period. The report on the celiac diseases drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by higher consumption of gluten-containing food, increasing prevalence of celiac diseases, and government initiatives.

Technavio's celiac diseases drugs market is segmented as below:

Market Scope
Base Year2022
End Year2027
Series Year2023-2027
Growth MomentumAccelerate
YOY 202315.85%
CAGR17.01%
Incremental Value$701.59mn

By Therapy

  • First line treatment
  • Second-line treatment

By Route Of Administration

  • Oral
  • Parenteral

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the inorganic growth strategies as one of the prime reasons driving the celiac diseases drugs market growth during the next few years. Also, increasing promising developments in celiac treatment and rising prevalence and diagnosis will lead to sizable demand in the market.

The report on the celiac diseases drugs market covers the following areas:

  • Celiac diseases drugs market sizing
  • Celiac diseases drugs market forecast
  • Celiac diseases drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading celiac diseases drugs market vendors that include 9 Meters Biopharma Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., AMYRA Biotech AG, Artielle Immunotherapeutics Inc, Avaxia Biologics Inc., BioLineRx Ltd., Bristol Myers Squibb Co., Calypso Biotech BV, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., ImmunogenX Inc., Johnson and Johnson, Precigen Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Vactech Oy, and Zedira GmbH. Also, the celiac diseases drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Therapy
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global celiac diseases drugs market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on global celiac diseases drugs market 2017 - 2021 ($ million)
  • 4.2 Therapy Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
  • 4.3 Route of Administration Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Therapy

  • 6.1 Market segments
  • Exhibit 30: Chart on Therapy - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Therapy - Market share 2022-2027 (%)
  • 6.2 Comparison by Therapy
  • Exhibit 32: Chart on Comparison by Therapy
  • Exhibit 33: Data Table on Comparison by Therapy
  • 6.3 First line treatment - Market size and forecast 2022-2027
  • Exhibit 34: Chart on First line treatment - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on First line treatment - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on First line treatment - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on First line treatment - Year-over-year growth 2022-2027 (%)
  • 6.4 Second-line treatment - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Second-line treatment - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Second-line treatment - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Second-line treatment - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Second-line treatment - Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Therapy
  • Exhibit 42: Market opportunity by Therapy ($ million)
  • Exhibit 43: Data Table on Market opportunity by Therapy ($ million)

7 Market Segmentation by Route of Administration

  • 7.1 Market segments
  • Exhibit 44: Chart on Route of Administration - Market share 2022-2027 (%)
  • Exhibit 45: Data Table on Route of Administration - Market share 2022-2027 (%)
  • 7.2 Comparison by Route of Administration
  • Exhibit 46: Chart on Comparison by Route of Administration
  • Exhibit 47: Data Table on Comparison by Route of Administration
  • 7.3 Oral - Market size and forecast 2022-2027
  • Exhibit 48: Chart on Oral - Market size and forecast 2022-2027 ($ million)
  • Exhibit 49: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
  • Exhibit 50: Chart on Oral - Year-over-year growth 2022-2027 (%)
  • Exhibit 51: Data Table on Oral - Year-over-year growth 2022-2027 (%)
  • 7.4 Parenteral - Market size and forecast 2022-2027
  • Exhibit 52: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
  • Exhibit 54: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
  • Exhibit 55: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)
  • 7.5 Market opportunity by Route of Administration
  • Exhibit 56: Market opportunity by Route of Administration ($ million)
  • Exhibit 57: Data Table on Market opportunity by Route of Administration ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 59: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibit 60: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 61: Chart on Geographic comparison
  • Exhibit 62: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 63: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 65: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 66: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 67: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 68: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 69: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 70: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 73: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 74: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 79: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 80: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 81: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 82: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Canada - Market size and forecast 2022-2027
  • Exhibit 83: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 84: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 85: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibit 86: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.9 Germany - Market size and forecast 2022-2027
  • Exhibit 87: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 88: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 89: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibit 90: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.10 UK - Market size and forecast 2022-2027
  • Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.11 China - Market size and forecast 2022-2027
  • Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 99: Market opportunity By Geographical Landscape ($ million)
  • Exhibit 100: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 101: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 103: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 104: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 105: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 106: Matrix on vendor position and classification
  • 12.3 Adaptive Biotechnologies Corp.
  • Exhibit 107: Adaptive Biotechnologies Corp. - Overview
  • Exhibit 108: Adaptive Biotechnologies Corp. - Product / Service
  • Exhibit 109: Adaptive Biotechnologies Corp. - Key offerings
  • 12.4 Almirall SA
  • Exhibit 110: Almirall SA - Overview
  • Exhibit 111: Almirall SA - Product / Service
  • Exhibit 112: Almirall SA - Key news
  • Exhibit 113: Almirall SA - Key offerings
  • 12.5 Amgen Inc.
  • Exhibit 114: Amgen Inc. - Overview
  • Exhibit 115: Amgen Inc. - Product / Service
  • Exhibit 116: Amgen Inc. - Key offerings
  • 12.6 AMYRA Biotech AG
  • Exhibit 117: AMYRA Biotech AG - Overview
  • Exhibit 118: AMYRA Biotech AG - Product / Service
  • Exhibit 119: AMYRA Biotech AG - Key offerings
  • 12.7 BioLineRx Ltd.
  • Exhibit 120: BioLineRx Ltd. - Overview
  • Exhibit 121: BioLineRx Ltd. - Product / Service
  • Exhibit 122: BioLineRx Ltd. - Key offerings
  • 12.8 Bristol Myers Squibb Co.
  • Exhibit 123: Bristol Myers Squibb Co. - Overview
  • Exhibit 124: Bristol Myers Squibb Co. - Product / Service
  • Exhibit 125: Bristol Myers Squibb Co. - Key news
  • Exhibit 126: Bristol Myers Squibb Co. - Key offerings
  • 12.9 Calypso Biotech BV
  • Exhibit 127: Calypso Biotech BV - Overview
  • Exhibit 128: Calypso Biotech BV - Product / Service
  • Exhibit 129: Calypso Biotech BV - Key offerings
  • 12.10 GlaxoSmithKline Plc
  • Exhibit 130: GlaxoSmithKline Plc - Overview
  • Exhibit 131: GlaxoSmithKline Plc - Business segments
  • Exhibit 132: GlaxoSmithKline Plc - Key news
  • Exhibit 133: GlaxoSmithKline Plc - Key offerings
  • Exhibit 134: GlaxoSmithKline Plc - Segment focus
  • 12.11 Glenmark Pharmaceuticals Ltd.
  • Exhibit 135: Glenmark Pharmaceuticals Ltd. - Overview
  • Exhibit 136: Glenmark Pharmaceuticals Ltd. - Product / Service
  • Exhibit 137: Glenmark Pharmaceuticals Ltd. - Key offerings
  • 12.12 ImmunogenX Inc.
  • Exhibit 138: ImmunogenX Inc. - Overview
  • Exhibit 139: ImmunogenX Inc. - Product / Service
  • Exhibit 140: ImmunogenX Inc. - Key offerings
  • 12.13 Johnson and Johnson
  • Exhibit 141: Johnson and Johnson - Overview
  • Exhibit 142: Johnson and Johnson - Business segments
  • Exhibit 143: Johnson and Johnson - Key news
  • Exhibit 144: Johnson and Johnson - Key offerings
  • Exhibit 145: Johnson and Johnson - Segment focus
  • 12.14 Precigen Inc.
  • Exhibit 146: Precigen Inc. - Overview
  • Exhibit 147: Precigen Inc. - Business segments
  • Exhibit 148: Precigen Inc. - Key offerings
  • Exhibit 149: Precigen Inc. - Segment focus
  • 12.15 Sanofi
  • Exhibit 150: Sanofi - Overview
  • Exhibit 151: Sanofi - Business segments
  • Exhibit 152: Sanofi - Key news
  • Exhibit 153: Sanofi - Key offerings
  • Exhibit 154: Sanofi - Segment focus
  • 12.16 Takeda Pharmaceutical Co. Ltd.
  • Exhibit 155: Takeda Pharmaceutical Co. Ltd. - Overview
  • Exhibit 156: Takeda Pharmaceutical Co. Ltd. - Product / Service
  • Exhibit 157: Takeda Pharmaceutical Co. Ltd. - Key news
  • Exhibit 158: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 12.17 Teva Pharmaceutical Industries Ltd.
  • Exhibit 159: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 160: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 161: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 163: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 164: Inclusions checklist
  • Exhibit 165: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 166: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 167: Research methodology
  • Exhibit 168: Validation techniques employed for market sizing
  • Exhibit 169: Information sources
  • 13.5 List of abbreviations
  • Exhibit 170: List of abbreviations